Owen Mumford has been awarded a distinction in the prestigious Red Dot awards for innovative product design for its Aidaptus single-use auto-injector launched in 2021. Aidaptus wins the Red Dot award for the category Product Design 2023.
Aidaptus is a single-use auto-injector created for the administration of a wide range of drugs and biologics which require subcutaneous delivery. Aidaptus features distinctive design elements that benefit both drug companies and patients, which helped to secure the award.
The auto adjust stopper sensing technology features a self-adjusting plunger that automatically adapts to different fill volumes in each syringe, with no change parts required. The versatile design also accommodates both 1mL and 2.25 mL prefilled glass syringes in the same compact base device. This provides pharmaceutical companies with a single solution for delivery of a variety of drug formulations.
In addition, the compact design and simple two-step injection process provide ease of use and confidence for those patients who require subcutaneous medication. The intuitive design is key to helping patients administer their own treatments in a home setting, helping to reduce the burden on healthcare practitioners and services.
“Red Dot is one of the most prestigious design competitions that is highly competitive, and we are honoured to be globally recognised with distinction in the Product Design 2023 category,” said Jarl Severn, CEO Owen Mumford. “We have previously enjoyed this accolade for our Unifine Pentips Plus pen needle and this news further underscores our ongoing pursuit and commitment to excellence in design.”
Aidaptus will help patients to self-administer their individual therapies for diseases such as rheumatoid arthritis, Crohn’s disease and multiple sclerosis.
